NGEN
NervGen Pharma Corp.
1.80$
+0.6%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.8% | +140.5% | -12.5% | -19.5% | -13.2% | -19.1% | +8.0% | -23.0% | +77.2% | -10.6% | +335.3% | |
| – | -19.5% | +148.9% | -12.3% | -19.8% | -13.3% | -19.5% | +8.3% | -23.5% | +79.9% | -10.7% | +341.9% | |
| – | -20.9% | +160.3% | -12.6% | -21.0% | -17.7% | -16.6% | +9.5% | -27.8% | +93.9% | -25.0% | +425.3% | |
| – | -20.9% | +160.3% | -12.6% | -21.0% | -17.3% | -16.6% | +9.3% | -27.8% | +93.4% | -25.0% | +425.3% | |
| – | +976.3% | -94.6% | +678.4% | -3.6% | +306.7% | -20.0% | -70.6% | +253.8% | -76.6% | +15.6% | +114.6% | |
| – | -2.3% | -2.5% | -3.0% | -2.9% | -2.8% | -3.5% | -2.1% | -3.5% | -3.4% | -3.5% | -3.3% | |
| – | +35.9% | -14.9% | +18.6% | -13.8% | +27.5% | -15.0% | +24.8% | -10.5% | +23.0% | -22.9% | +380.1% | |
| – | +36.5% | -14.8% | +18.9% | -13.7% | +27.7% | -14.9% | +24.8% | -10.5% | +23.0% | -22.9% | +380.1% | |
| – | +1.8% | +1.7% | +1.3% | +1.4% | +1.6% | -16.3% | -28.7% | -42.6% | -74.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -139.5% | – | -33.8% | -26.6% | -71.9% | -46.3% | -166.8% | – | – | +59.3% | +212.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.3% | +1.0% | +16.2% | +0.2% | +0.4% | +0.5% | +1.8% | +1.7% | -1.1% | +10.5% | +15.7% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.